Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-4731(78)90629-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays.
FEBS Open Bio
January 2025
Synthetic and Systems Biology Unit, Institute of Biochemistry, HUN-REN Biological Research Centre, Szeged, Hungary.
Malaria, a life-threatening disease caused by Plasmodium parasites, continues to pose a significant global health threat, with nearly 250 million infections and over 600 000 deaths reported annually by the WHO. Fighting malaria is particularly challenging partly due to the complex life cycle of the parasite. However, technological breakthroughs such as the development of the nucleoside-modified mRNA lipid nanoparticle (mRNA-LNP) vaccine platform, along with the discovery of novel conserved Plasmodium antigens such as the E140 protein, present new opportunities in malaria prevention.
View Article and Find Full Text PDFA broad spectrum Shigella vaccine based on VirG multiepitope region produced in a cell-free system.
NPJ Vaccines
January 2025
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.
View Article and Find Full Text PDFEvaluating small extracellular vesicle-based vaccination across heterologous strains isolated from wastewater.
Infect Immun
January 2025
Microbiology and Cell Science Department, IFAS, University of Florida, Gainesville, Florida, USA.
infections pose significant public health challenges worldwide. The diversity of strains, particularly those isolated from environmental and clinical sources, necessitates innovative approaches to prevention and treatment. Previous research has shown that small extracellular vesicles (sEVs) produced by macrophages during Typhimurium infection can induce robust immune responses when used as a vaccine, offering complete protection in systemic infection models.
View Article and Find Full Text PDFAn experimental chimeric hepatitis E virus vaccine elicits both local and systemic immune responses.
Front Microbiol
December 2024
Infection Biology Laboratory, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONI-CET-UNT, Tucumán, Argentina.
Introduction: The development of a hepatitis E virus (HEV) vaccine is critical, with ORF2 capsid protein as the main target. We previously demonstrated that oral coadministration of recombinant ORF2 with immunomodulatory bacterium-like-particles (IBLP) induces a specific immune response in mice, particularly using IBLP derived from IBL027 (IBLP027), which was effective in eliciting a local humoral response. IBLP are non-live bacteria with adjuvant and carrier properties, serving as a platform for exposing proteins or antigens fused to LysM (lysine motif) domains, protein modules that bind to cell wall polysaccharides like peptidoglycan.
View Article and Find Full Text PDFAnti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.
PLoS One
January 2025
Office of Public Health Data, Surveillance and Technology, US Centers for Disease Control, Atlanta, Georgia, United States of America.
People with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of infection-induced antibodies in sera following a positive COVID-19 test result was compared between patients with and without IC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!